Understand the source comparison
Cagrilintide Satiety Results Timeline — Comparison Across Dose Levels
0.3mg weekly 36–72 hours Week 5–7 Week 10–14 12–15% from baseline Subtherapeutic for most metabolic research applications. Gastric effect present but central suppression inconsistent across subjects 0.6mg weekly 24–48 hours Week 4–6 Week 8–10 18–22% from basel
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 0.3mg weekly
- 36–72 hours
- Week 5–7
- Week 10–14
- 12–15% from baseline
- Subtherapeutic for most metabolic research applications. Gastric effect present but central suppression inconsistent across subjects
- 0.6mg weekly
- 24–48 hours
- Week 4–6
- Week 8–10
- 18–22% from baseline
- Standard research dose. Produces reliable phase progression and sustained satiety without excessive GI adverse events
- 1.2mg weekly
- 12–24 hours
- Week 3–5
- Week 7–9
- 24–28% from baseline
- High-intensity protocol. Accelerates all phases but increases nausea incidence to 40–50% during titration
- 2.4mg weekly (investigational)
- 8–18 hours
- Week 2–4
- Week 6–8
- 30–35% from baseline
- Experimental only. Satiety intensity often exceeds tolerability; early discontinuation common due to prolonged nausea
- Higher doses compress the timeline but increase GI side effect burden. The 0.6mg dose produces the most consistent phase progression without intolerable nausea. Gastric adaptation occurs before central suppression peaks, allowing the body to adjust incrementally.